CL2025001237A1 - Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos - Google Patents

Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos

Info

Publication number
CL2025001237A1
CL2025001237A1 CL2025001237A CL2025001237A CL2025001237A1 CL 2025001237 A1 CL2025001237 A1 CL 2025001237A1 CL 2025001237 A CL2025001237 A CL 2025001237A CL 2025001237 A CL2025001237 A CL 2025001237A CL 2025001237 A1 CL2025001237 A1 CL 2025001237A1
Authority
CL
Chile
Prior art keywords
autoantibody
treatment
immunoglobulin
multispecific molecules
induced diseases
Prior art date
Application number
CL2025001237A
Other languages
English (en)
Inventor
Siva Charan Devanaboyina Venkata
Li Peng
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2025001237A1 publication Critical patent/CL2025001237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a moléculas multiespecíficas que se unen a inmunoglobulina y a una diana de reciclaje. La unión de la inmunoglobulina y una diana de reciclaje da como resultado la degradación de la inmunoglobulina y, en ciertas realizaciones, el reciclaje de la molécula multiespecífica. Se cree que las moléculas multiespecíficas de la presente invención son útiles en el tratamiento de enfermedades inducidas por autoanticuerpos.
CL2025001237A 2022-10-26 2025-04-25 Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos CL2025001237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263419549P 2022-10-26 2022-10-26

Publications (1)

Publication Number Publication Date
CL2025001237A1 true CL2025001237A1 (es) 2025-06-23

Family

ID=88874631

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001237A CL2025001237A1 (es) 2022-10-26 2025-04-25 Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos

Country Status (10)

Country Link
US (1) US20260042865A1 (es)
EP (1) EP4608864A1 (es)
JP (1) JP2026500893A (es)
KR (1) KR20250094708A (es)
CN (1) CN120359240A (es)
AU (1) AU2023367846A1 (es)
CL (1) CL2025001237A1 (es)
IL (1) IL320335A (es)
MX (1) MX2025004882A (es)
WO (1) WO2024092033A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025146152A1 (zh) * 2024-01-04 2025-07-10 上海宝济药业股份有限公司 一种药物组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
WO2018102668A1 (en) * 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
US20230183379A1 (en) * 2018-11-20 2023-06-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
AU2019404061A1 (en) * 2018-12-19 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
CN117279618A (zh) * 2020-11-30 2023-12-22 弗莱德哈钦森癌症中心 用于靶标分子的选择性耗竭的组合物和方法
EP4281115A1 (en) * 2021-01-19 2023-11-29 Novartis AG Degradation of extracellular targets

Also Published As

Publication number Publication date
IL320335A (en) 2025-06-01
US20260042865A1 (en) 2026-02-12
EP4608864A1 (en) 2025-09-03
CN120359240A (zh) 2025-07-22
AU2023367846A1 (en) 2025-05-01
WO2024092033A1 (en) 2024-05-02
JP2026500893A (ja) 2026-01-09
MX2025004882A (es) 2025-06-02
KR20250094708A (ko) 2025-06-25

Similar Documents

Publication Publication Date Title
CL2022003077A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
CL2025001237A1 (es) Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos
CO2022011332A2 (es) Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CO2019003951A2 (es) Proteínas de unión a cd123 y composiciones y métodos relacionados
MX2022002977A (es) Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3.
PE20190907A1 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
AR085138A1 (es) VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
ECSP24044371A (es) Moléculas de anticuerpo y conjugados
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
BR112022013575A2 (pt) Anticorpos conjugados com moléculas de ácido graxo e usos dos mesmos
MX2024008174A (es) Metodos para tratar el cancer urotelial musculo-invasivo o el cancer de vejiga musculo-invasivo con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
MX2025000437A (es) Inmunoconjugados de epcam y usos de estos
MX2023010813A (es) Anticuerpos anti-alpp/alppl2 y conjugados de anticuerpo-farmaco.
MX2021009533A (es) Composiciones y metodos para usar anticuerpos bispecificos para unirse al complemento y a un antigeno objetivo.
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
CL2025000297A1 (es) Anticuerpos anti-ccr8 y métodos de uso
MX2022005717A (es) Moleculas de anticuerpos anti-siglec-9.
CL2020000755A1 (es) Moléculas de unión a antígeno biespecíficas que se unen a un antígeno blanco de staphylococcus y a un componente del complemento y usos de las mismas.
DOP2025000023A (es) Proteínas de unión a nkg2d, cd16 y ceacam5
MX2024006205A (es) Composiciones que comprenden agentes de unión multiespecíficos potenciados para una respuesta inmunitaria.